Growth Hormone Clinical Trial
Official title:
Growth Hormone 120 Minutes Following a Single Low-dose of Amino Acids in Healthy Subjects.
NCT number | NCT01540773 |
Other study ID # | PBRC 10043 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | October 2011 |
Est. completion date | March 2012 |
Verified date | October 2018 |
Source | Pennington Biomedical Research Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of the study is to confirm the results of a prior study that demonstrated pills containing two amino acids which are in foods increased growth hormone and insulin-like growth factor-1.
Status | Completed |
Enrollment | 16 |
Est. completion date | March 2012 |
Est. primary completion date | December 2011 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - healthy males and healthy females - Between 18 and 70 years Exclusion Criteria: - Pregnant or nursing - Taking any chronic medication including birth control pills. |
Country | Name | City | State |
---|---|---|---|
United States | Pennington Biomedical Research Center | Baton Rouge | Louisiana |
Lead Sponsor | Collaborator |
---|---|
Pennington Biomedical Research Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change From Baseline of Growth Hormone | Measure human growth hormone at times 0-120 minutes on two occasions about one week apart. On one occasion, the proprietary amino acid derivative blend will be given orally at time 0 in capsule form, and on the other occasion the capsules will contain no amino acids. | 0-120 minutes, at Baseline and post dose, week 1 and week 3 | |
Primary | Area Under the Curve of Growth Hormone Over Baseline | Measure human growth hormone at times 0-120 minutes on two occasions about one week apart. On one occasion, the proprietary amino acid derivative blend will be given orally at time 0 in capsule form, and on the other occasion the capsules will contain no amino acids. | 0-120 minutes, at Baseline and post dose, week 1 and week 3 | |
Secondary | Insulin-like Growth Factor 1 | Measure IGF-1 8 hours following the administration of the capsules containing the proprietary amino acid derivative blend or placebo | 8 hours following administration |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04079010 -
The Effect of Blood Flow Restriction With and Without Arginine on Physical Performance and Growth Hormone
|
N/A | |
Completed |
NCT00562796 -
Prevalence and Cardiovascular Effects of Growth Hormone Deficiency in Abdominal Obesity
|
N/A | |
Completed |
NCT05574894 -
Effect of GH Supplementation on the Blastocyst Euploid Rate in AMA Patients--A Retrospective Cohort Study
|
Phase 3 | |
Completed |
NCT01158612 -
The Effect of Local Injectet GH on the Collagen Synthesis in the Ligamentum Patella
|
N/A | |
Recruiting |
NCT05447208 -
Effect of GH on the Blastocyst Euploid Rate in AMA Patients
|
Phase 3 | |
Completed |
NCT00966134 -
Ghrelin, Growth Hormone and Growth Factors at High Altitude
|
N/A | |
Active, not recruiting |
NCT06433375 -
Evaluation of the Efficacy of Growth Hormone on Healing of Periapical Pathosis
|
N/A |